Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Genespire","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$17.3 million","upfrontCash":"Undisclosed","newsHeadline":"Genespire Secures \u20ac16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed"},{"orgOrder":0,"company":"Genespire","sponsor":"Genespire","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genespire and SR-Tiget Announce Alliance for the Development of Transformative Gene Therapies for Genetic Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Genespire

    Menu

    Genespire

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Genespire

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Genespire and SR-Tiget Announce Alliance for the Development of Transformative Gene Therapies for Genetic Diseases

              Details:

              Under the terms of the alliance, Genespire and SR-Tiget will study and further develop novel gene therapies, which have the unique potential to address severe unmet medical need and exploit gene editing and lentiviral vector technologies developed by SR-Tiget.

              Lead Product(s): MicroRNA-regulated lentiviral vectors

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

              Recipient: SR-Tiget

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Genespire

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Genespire Secures €16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies

              Details:

              The funds will be used to advance Genespire’s leading-edge platform technologies towards the development of novel gene therapies in primary immunodeficiencies and metabolic genetic diseases.

              Lead Product(s): Gene Therapy

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Sofinnova Partners

              Deal Size: $17.3 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing April 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY